References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350.
- Bruni L, Barrionuevo-Rosas L, Albero G, et al. Human Papillomavirus and Related Diseases in the World. ICO/IARC Information Centre on HPV and Cancer; Summary Report; 17 June 2019.
- Kovachev S, Slavov V. Prevalence of human papillomavirus infection in women in Bulgaria: a 2017 update. J Med Virol. 2018;90(6):1142–1149.
- Mehta AM, Mooij M, Branković I, et al. Cervical carcinogenesis and immune response gene polymorphisms: a review. J Immunol Res. 2017;2017:8913860.
- Lin M, Ye M, Zhou J, et al. Recent advances on the molecular mechanism of cervical carcinogenesis based on systems biology technologies. Comput Struct Biotechnol J. 2019;17:241–250.
- Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(2):123–137.
- Asciutto KC, Henic E, Darlin L, et al. Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable. Acta Obstet Gynecol Scand. 2016;95(11):1251–1257.
- Cho HW, So KA, Lee JK, et al. Type-specific persistence or regression of human papillomavirus genotypes in women with cervical intraepithelial neoplasia 1: a prospective cohort study. Obstet Gynecol Sci. 2015;58(1):40–45.
- Sliva J, Pantzartzi C, Votava M. Inosine Pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases. Adv Ther. 2019;36(8):1878–1905.
- Eliseeva MY, Manukhin IB, Mynbaev OA, et al. Antiviral effect of isoprinosine in HPV-associated diseases. Obstet Gynecol. 2012;2:107–114.
- Urbaniak GC, Plous S. Research randomizer [computer program]. Version 4.0. [accessed 2013 June 22; cited 2020 Mar 23]. Available from: http://www.randomizer.org/.
- Zhou C, Tuong ZK, Frazer IH. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol. 2019;9:682
- Van de Wall S, Nijman HW, Daemen T. HPV-specific immunotherapy: key role for immunomodulators. Anticancer Agents Med Chem. 2014;14(2):265–279.
- Nejmark BA, Kondrat’eva JS, Zologina VS, et al. Effectiveness of combined treatment of HPV infection. Urologiia. 2015;42(2):39–40.
- Kedrova AG, Podisov YI, Kuznetsov VV, et al. Role of antiviral therapy in the complex treatment of patients with epithelial dysplasias and preinvasive cancer of the cervix uteri. Akuš Ginekol. 2006;6:27–30.
- Sadoul G, Beuret T. Treatment of cervical and vulvar condylomata by CO2 laser also with a immunostimulant. Rev Fr Gynecol Obstet. 1984;79(11):681–684. (French)
- Davidson-Parker J, Dinsmore W, Khan MH, et al. Immunotherapy of genital warts with Inosine Pranobex and conventional treatment: double blind placebo controlled study. Genitourin Med. 1988;64(6):383–386.
- Mohanty CK, Scott SC. Immunotherapy of genital warts with Inosine Pranobex (Imunovir): preliminary study. Genitourin Med. 1986;62(5):352–355.
- Tay SK. Efficacy of Inosine Pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study. Int J STD Aids. 1996;7(4):276–280.